NCT07159620

Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients

A Prospective Single-Arm Clinical Study of Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 27 (estimated)
• Sponsor: The First Affiliated Hospital of Soochow University · Academic / Other
• Sex: All
• Age: 14 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

ETP-ALL like patients have poor outcomes and prognosis, and the optimal therapeutic approaches are poorly characterized. The goal of this clinical trial is to evaluate the efficacy and safety of the venetoclax combined with azacitidine, chidamide, vindesine, and dexamethasone regimen in newly diagnosed ETP-ALL like patinets (including ETP-ALL, near ETP-ALL and T-ALL with myeloid mutations) .

Conditions

• Adult T-cell Leukemia/Lymphoma

Interventions

Type	Name	Description
DRUG	VEN (Venetoclax)	Orally
DRUG	Azacitidine (AZA)	Subcutaneous injection
DRUG	Chidamide	Orally
DRUG	vindesine	intravenous infusion
DRUG	Dexamethasone	intravenous infusion or orally

Timeline

• Start date: 2025-09-01
• Primary completion: 2028-09-01
• Completion: 2030-09-01
• First posted: 2025-09-08
• Last updated: 2025-09-08

Locations

1 site across 1 country: China